CIITA (Class II Major Histocompatibility Complex Transactivator) is the master transcriptional coactivator that controls the expression of MHC class II genes, making it essential for adaptive immune responses[1]. While primarily studied in immune cells, CIITA has emerged as a relevant player in neuroinflammation and neurodegenerative through its regulation of antigen presentation in the brain[2]. The protein functions as a non-DNA-binding coactivator that orchestrates the assembly of transcription factors at MHC class II promoters.
| Property | Value |
|---|---|
| Gene Symbol | CIITA |
| Official Name | Class II Major Histocompatibility Complex Transactivator |
| Aliases | MHC2TA, NLRA |
| Chromosomal Location | 16p13.13 |
| NCBI Gene ID | 4261 |
| UniProt ID | P33076 |
| Ensembl ID | ENSG00000179583 |
| Protein Class | Transcriptional coactivator |
CIITA (~1130 amino acids) contains several functional domains:
The structure allows CIITA to serve as a molecular scaffold, recruiting multiple transcriptional machinery components to MHC class II promoters.
CIITA is absolutely required for MHC class II gene transcription:
Under certain conditions, CIITA can be expressed in non-immune cells:
In Alzheimer's disease, CIITA contributes to neuroinflammation:
CIITA involvement in PD includes:
In ALS, CIITA plays significant roles:
While not a primary neurodegenerative disease, MS provides insights into CIITA's role in neuroinflammation:
In the central nervous system, CIITA expression is typically low but inducible:
Targeting CIITA-related pathways offers therapeutic opportunities:
Key questions remain:
Boss JM, Jensen PE. Transcriptional regulation of the MHC class II antigen presentation pathway. Curr Opin Immunol. 2003. ↩︎ ↩︎ ↩︎
Meda L, et al. MHC class II expression in Alzheimer's disease brain. Neurobiol Aging. 1995. ↩︎ ↩︎ ↩︎
Muhlethaler-Mottet A, et al. The master regulator CIITA: A network controlling MHC class II gene expression. Int J Biochem Cell Biol. 2008. ↩︎
Kwon JA, et al. CIITA and chromatin remodeling. Immunol Rev. 2003. ↩︎
McManus RM, et al. MHC class II expression in Alzheimer's disease microglia. J Neuroinflammation. 2020. ↩︎
Gate D, et al. T cells in Alzheimer's disease. Nat Neurosci. 2020. ↩︎
Brochard V, et al. Infiltration of CD4+ lymphocytes in Parkinson's disease brain. J Neuroinflammation. 2009. ↩︎
Takeshita Y, et al. Blood-brain barrier dysfunction in neurodegenerative. Neurobiol Dis. 2020. ↩︎
Chiu IM, et al. T cells from ALS patients respond to disease antigens. Sci Transl Med. 2008. ↩︎ ↩︎
Bencimon C, et al. MHC class II in multiple sclerosis: A new marker for disease progression. Neurology. 2005. ↩︎